{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:54:21Z","timestamp":1770965661284,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.acvd.2015.05.005","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T01:07:00Z","timestamp":1435021620000},"page":"544-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey"],"prefix":"10.1016","volume":"108","author":[{"given":"Pierre","family":"Sabouret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Annick","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois-Emery","family":"Cott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Deret-Bixio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Rushton-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2015.05.005_bib0240","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart Study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2015.05.005_bib0245","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.lpm.2007.09.019","article-title":"[Atrial fibrillation: the most common arrhythmia]","volume":"37","author":"Le Heuzey","year":"2008","journal-title":"Presse Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.acvd.2010.11.012","article-title":"Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data","volume":"104","author":"Charlemagne","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2015.05.005_bib0255","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2015.05.005_bib0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2015.05.005_bib0265","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2015.05.005_bib0270","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.05.005_bib0275","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u00a0\u2013\u00a0Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2015.05.005_bib0280","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0285","first-page":"1797","article-title":"[Use and monitoring of vitamin K antagonists in everyday medical practice. French results of the international ISAM study of patients with nonvalvular atrial fibrillation]","volume":"35","author":"Mahe","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0290","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0295","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2015.05.005_bib0300","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.05.005_bib0305","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00392-014-0726-y","article-title":"Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database","volume":"103","author":"Sabouret","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.acvd.2015.05.005_bib0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2015.05.005_bib0315","series-title":"Applied Mixed Models in Medicine","author":"Brown","year":"1999"},{"key":"10.1016\/j.acvd.2015.05.005_bib0320","doi-asserted-by":"crossref","first-page":"638e4","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0325","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.acvd.2010.06.001","article-title":"Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study","volume":"103","author":"Cohen","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2015.05.005_bib0330","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u00a0\u2013\u00a0European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2015.05.005_bib0335","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","article-title":"Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.05.005_bib0340","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/clc.22272","article-title":"Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry","volume":"37","author":"Kirchhof","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.acvd.2015.05.005_bib0345","first-page":"601e1","article-title":"Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"167","author":"O\u2019Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2015.05.005_bib0350","doi-asserted-by":"crossref","first-page":"e67806","DOI":"10.1371\/journal.pone.0067806","article-title":"Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice","volume":"8","author":"Arts","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2015.05.005_bib0355","doi-asserted-by":"crossref","first-page":"e000110","DOI":"10.1161\/JAHA.113.000110","article-title":"Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry","volume":"2","author":"Fosbol","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2015.05.005_bib0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2261-12-12","article-title":"The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey","volume":"12","author":"Gerber","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.acvd.2015.05.005_bib0365","first-page":"e305","article-title":"Are family physicians using the CHADS2 score? Is it useful for assessing risk of stroke in patients with atrial fibrillation?","volume":"57","author":"Klein","year":"2011","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.acvd.2015.05.005_bib0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.annemergmed.2004.01.010","article-title":"Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study G. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study","volume":"44","author":"Laguna","year":"2004","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0375","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2015.05.005_bib0380","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2006.10.047","article-title":"Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"49","author":"Dagres","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.05.005_bib0385","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0390","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1503\/cmaj.121218","article-title":"Rates of hemorrhage during warfarin therapy for atrial fibrillation","volume":"185","author":"Gomes","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.acvd.2015.05.005_bib0395","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2015.05.005_bib0400","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.clinthera.2014.07.016","article-title":"Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries","volume":"36","author":"Cotte","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.acvd.2015.05.005_bib0405","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","article-title":"The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study","volume":"167","author":"Kimmel","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2015.05.005_bib0410","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","article-title":"Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes","volume":"35","author":"Azoulay","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2015.05.005_bib0415","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11319540-000000000-00000","article-title":"Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study","volume":"27","author":"Tulner","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.acvd.2015.05.005_bib0420","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2008.03059.x","article-title":"Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?","volume":"6","author":"Gallagher","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2015.05.005_bib0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/europace\/eur141","article-title":"An epidemic of atrial fibrillation?","volume":"13","author":"Olesen","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2015.05.005_bib0430","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cpcardiol.2014.07.001","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation","volume":"39","author":"Senoo","year":"2014","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.acvd.2015.05.005_bib0435","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2015.05.005_bib0440","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3111\/13696998.2014.923891","article-title":"Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin","volume":"17","author":"Lanitis","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.acvd.2015.05.005_bib0445","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.acvd.2014.04.009","article-title":"Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective","volume":"107","author":"Chevalier","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2015.05.005_bib0450","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","article-title":"National trends in oral anticoagulant use in the United States, 2007 to 2011","volume":"5","author":"Kirley","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.acvd.2015.05.005_bib0455","series-title":"European Society of Cardiology Congress. Satellite Symposium","article-title":"Introduction and status update of GARFIELD","author":"Kakkar","year":"2014"},{"key":"10.1016\/j.acvd.2015.05.005_bib0460","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1747-4949.2010.00574.x","article-title":"Improving stroke care: a French health-care organiser's perspective","volume":"6","author":"Lebrun","year":"2011","journal-title":"Int J Stroke"},{"key":"10.1016\/j.acvd.2015.05.005_bib0470","series-title":"ANNEXA\u2122 a phase 3 randomized, double blind, placebo controlled trial, demonstrating reversal of apixaban induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors","author":"Crowther","year":"2014"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213615001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213615001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:42:41Z","timestamp":1761745361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213615001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1875213615001059"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2015.05.005","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2015.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}